Go Pro
LON:TRX

Tissue Regenix Group (TRX) Share Price, News & Analysis

Tissue Regenix Group logo
GBX 0.07 0.00 (0.00%)
As of 01/6/2026

About Tissue Regenix Group Stock (LON:TRX)

Key Stats

Today's Range
0.07
0.07
50-Day Range
0.07
0.07
52-Week Range
4.77
66
Volume
N/A
Average Volume
169,613 shs
Market Capitalization
£51.65 thousand
P/E Ratio
N/A
Dividend Yield
4.12%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care. In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

Receive TRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TRX Stock News Headlines

Tissue Regenix Group PLC
CellRight Tech: Private Equity Funding Secured
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Tissue Regenix Scraps Sale Plans, Flags Profit Ahead
Tissue Regenix Group Regulatory News
Tissue Regenix Group Share Chat (TRX)
See More Headlines

TRX Stock Analysis - Frequently Asked Questions

Tissue Regenix Group's stock was trading at GBX 0.07 on January 1st, 2026. Since then, TRX shares have increased by 0.0% and is now trading at GBX 0.07.

Tissue Regenix Group plc (LON:TRX) announced its earnings results on Wednesday, September, 2nd. The company reported ($0.16) EPS for the quarter. Tissue Regenix Group had a negative trailing twelve-month return on equity of 2.38% and a negative net margin of 2.49%.

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank (SWDBY), Trevena (TRVN) and Barrick Gold (ABX).

Company Calendar

Last Earnings
9/02/2020
Today
8/03/2026

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Materials
Industry
Metals & Mining
Sub-Industry
Precious Metals & Minerals
Current Symbol
LON:TRX
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (1.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
0.14
P/E Growth
N/A
Net Income
-£1.11 million
Net Margins
-2.49%
Pretax Margin
N/A
Return on Equity
-2.38%
Return on Assets
0.50%

Debt

Debt-to-Equity Ratio
35.10
Current Ratio
3.46
Quick Ratio
2.36

Sales & Book Value

Annual Sales
£27.75 million
Price / Sales
0.00
Cash Flow
GBX 0.01 per share
Price / Cash Flow
5.70
Book Value
GBX 41.58 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
71,235,000
Free Float
N/A
Market Cap
£51.65 thousand
Optionable
Not Optionable
Beta
1.61
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (LON:TRX) was last updated on 8/3/2026 by MarketBeat.com Staff.
From Our Partners